Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
暂无分享,去创建一个
W. Chung | R. Nussbaum | D. Steinemann | F. Couch | J. Chang-Claude | O. Olopade | T. Rebbeck | B. Karlan | J. Benítez | R. Eeles | A. Spurdle | M. Southey | F. Lose | D. Easton | G. Rennert | P. Pharoah | M. Greene | K. Offit | A. Antoniou | Å. Borg | S. Buys | D. Eccles | D. Evans | G. Chenevix-Trench | H. Nevanlinna | U. Hamann | Ana-Teresa Maia | C. Lázaro | K. Nathanson | S. Orsulic | J. Garber | M. Schmidt | Andrew Lee | K. Aittomäki | H. Meijers-Heijboer | A. Meindl | R. Schmutzler | Xianshu Wang | A. Rudolph | I. Andrulis | G. Glendon | A. Mulligan | P. Radice | P. Peterlongo | S. Manoukian | A. Jakubowska | J. Lubiński | K. Durda | A. Toland | F. Fostira | J. Simard | S. Neuhausen | C. Sutter | S. Wang-gohrke | M. Robson | L. McGuffog | A. Godwin | J. Brunet | E. Friedman | M. Friedlander | A. Osorio | N. Ditsch | H. V. van Doorn | S. Tchatchou | B. Wappenschmidt | S. Domchek | D. Stoppa-Lyonnet | N. Lindor | M. Porteous | A. Viel | A. Martayan | G. Giannini | D. Frost | O. Sinilnikova | S. Mazoyer | C. Houdayer | C. Engel | C. Singer | C. Szabo | K. Claes | J. Rantala | R. Platte | B. Arun | U. Jensen | F. Damiola | A. Arason | O. Díez | P. Pujol | S. Hodgson | K. Moysich | L. Walker | Bowang Chen | G. Scuvera | L. Side | T. Hansen | B. Buecher | A. Gerdes | M. Ausems | D. Goldgar | K. Kuchenbaecker | M. Thomassen | Liying Zhang | B. Ejlertsen | M. Vreeswijk | J. Collée | J. Lester | T. Cole | C. Cybulski | M. Teixeira | A. Brady | M. Rogers | A. Bojesen | A. Miron | J. Weitzel | K. Blazer | M. Tischkowitz | J. Chiquette | N. Hoogerbrugge | O. Caron | B. Bressac-de Paillerets | K. Kast | K. Rhiem | S. Wilkening | B. Peissel | A. H. van der Hout | P. Morrison | C. Phelan | J. Gronwald | M. Rookus | L. Feliubadaló | L. Izatt | T. V. van Os | E. Oláh | C. Brewer | R. Davidson | C. Olswold | P. Soucy | D. Barrowdale | S. Healey | M. Piedmonte | I. Blanco | M. Montagna | E. J. van Rensburg | R. Janavicius | S. Ellis | J. Adlard | J. Cook | A. Donaldson | C. Delnatte | I. Coupier | L. Venat-Bouvet | L. Papi | M. Tibiletti | N. Arnold | A. Gehrig | D. Niederacher | H. Plendl | R. Varon‐Mateeva | G. Rodriguez | C. Rappaport | G. Pfeiler | M. Tea | Y. Laitman | I. Pedersen | L. Jønson | Y. Ding | P. Mai | M. de la Hoya | C. M. Dorfling | J. Barwell | M. Barile | N. Boutry‐Kryza | M. Belotti | L. Golmard | L. Walker | V. Joseph | G. Sukiennicki | A. Berger | L. Barjhoux | A. Vratimos | M. S. Askmalm | H. Ehrencrona | D. Zaffaroni | M. J. Kennedy | Daphne Geschwantler Kaulich | L. Copeland | T. Van Maerken | P. Segura | F. H. van der Baan | M. Corines | F. Mariette | S. Fortuzzi | Claire Foo | A. Lee | Filomena Ficarazzi | Lauren M. Jacobs | A. von Wachenfeldt | C. Martínez‐Bouzas | L. Matricardi | Katarzyna Jaworska–Bieniek | E. G. Gómez Garcia | Edye E Conway | T. Cole | J. Cook | M. Kennedy | Capucine Delnatte | Radka Platte | Steve Ellis | Muriel Belotti | E. Friedman | Stefano Fortuzzi | M. Teixeira | Curtis L. Olswold | Johanna Rantala | D. Evans | Frederieke H. van der Baan
[1] U. Vogel,et al. Association between Polymorphisms in Glutathione Peroxidase and Selenoprotein P Genes, Glutathione Peroxidase Activity, HRT Use and Breast Cancer Risk , 2013, PloS one.
[2] J. Chang-Claude,et al. A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk , 2013, Human molecular genetics.
[3] D. Altshuler,et al. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk , 2013, PLoS genetics.
[4] D. Easton,et al. Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High‐Risk Mutations , 2012, Genetic epidemiology.
[5] W. Willett,et al. A genome-wide association study identifies alleles in FGFR 2 associated with risk of sporadic postmenopausal breast cancer , 2012 .
[6] Christiana Kartsonaki,et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.
[7] J. Hesketh,et al. Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer , 2010, Genes & Nutrition.
[8] Theodore R Holford,et al. Molecular and Cellular Pathobiology Transcriptional Profiling Analyses , 2022 .
[9] V. Pankratz,et al. Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers , 2010 .
[10] David N. Rider,et al. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies , 2008, Breast Cancer Research.
[11] J. Brisson,et al. Vitamin D Pathway Polymorphisms in Relation to Mammographic Breast Density , 2008, Cancer Epidemiology Biomarkers & Prevention.
[12] M. Pike,et al. IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) , 2008, PloS one.
[13] J. Brisson,et al. Genetic Polymorphisms Involved in Insulin-like Growth Factor (IGF) Pathway in Relation to Mammographic Breast Density and IGF Levels , 2008, Cancer Epidemiology Biomarkers & Prevention.
[14] C. Begg,et al. Variation of breast cancer risk among BRCA1/2 carriers. , 2008, JAMA.
[15] D. Grobbee,et al. Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density , 2008, Breast Cancer Research and Treatment.
[16] F. Couch,et al. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. , 2007, American journal of human genetics.
[17] B. Ponder,et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Georgia Chenevix-Trench,et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.
[19] E. Friedman,et al. Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.
[20] J. Simard,et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.